Cargando…
Update on the management and treatment of viral hepatitis
This review aims to summarize the current evidence on the treatment of viral hepatitis, focusing on its clinical management. Also, future treatment options and areas of potential research interest are detailed. PubMed and Scopus databases were searched for primary studies published within the last t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218370/ https://www.ncbi.nlm.nih.gov/pubmed/34163109 http://dx.doi.org/10.3748/wjg.v27.i23.3249 |
_version_ | 1783710752204390400 |
---|---|
author | Almeida, Patricia Holanda Matielo, Celso E L Curvelo, Lilian A Rocco, Rodrigo A Felga, Guilherme Della Guardia, Bianca Boteon, Yuri L |
author_facet | Almeida, Patricia Holanda Matielo, Celso E L Curvelo, Lilian A Rocco, Rodrigo A Felga, Guilherme Della Guardia, Bianca Boteon, Yuri L |
author_sort | Almeida, Patricia Holanda |
collection | PubMed |
description | This review aims to summarize the current evidence on the treatment of viral hepatitis, focusing on its clinical management. Also, future treatment options and areas of potential research interest are detailed. PubMed and Scopus databases were searched for primary studies published within the last ten years. Keywords included hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus, hepatitis D virus (HDV), hepatitis E virus, and treatment. Outcomes reported in the studies were summarized, tabulated, and synthesized. Significant advances in viral hepatitis treatment were accomplished, such as the advent of curative therapies for hepatitis C and the development and improvement of hepatitis A, hepatitis B, and hepatitis E vaccination. Drugs that cure hepatitis B, going beyond viral suppression, are so far unavailable; however, targeted antiviral drugs against HBV (immunomodulatory therapies and gene silencing technologies) are promising approaches to eradicating the virus. Ultimately, high vaccination coverage and large-scale test-and-treat programmes with high screening rates may eliminate viral hepatitis and mitigate their burden on health systems. The development of curative hepatitis C treatment renewed the enthusiasm for curing hepatitis B, albeit further investigation is required. Novel therapeutic options targeting HDV life cycle are currently under clinical investigation. |
format | Online Article Text |
id | pubmed-8218370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-82183702021-06-22 Update on the management and treatment of viral hepatitis Almeida, Patricia Holanda Matielo, Celso E L Curvelo, Lilian A Rocco, Rodrigo A Felga, Guilherme Della Guardia, Bianca Boteon, Yuri L World J Gastroenterol Minireviews This review aims to summarize the current evidence on the treatment of viral hepatitis, focusing on its clinical management. Also, future treatment options and areas of potential research interest are detailed. PubMed and Scopus databases were searched for primary studies published within the last ten years. Keywords included hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus, hepatitis D virus (HDV), hepatitis E virus, and treatment. Outcomes reported in the studies were summarized, tabulated, and synthesized. Significant advances in viral hepatitis treatment were accomplished, such as the advent of curative therapies for hepatitis C and the development and improvement of hepatitis A, hepatitis B, and hepatitis E vaccination. Drugs that cure hepatitis B, going beyond viral suppression, are so far unavailable; however, targeted antiviral drugs against HBV (immunomodulatory therapies and gene silencing technologies) are promising approaches to eradicating the virus. Ultimately, high vaccination coverage and large-scale test-and-treat programmes with high screening rates may eliminate viral hepatitis and mitigate their burden on health systems. The development of curative hepatitis C treatment renewed the enthusiasm for curing hepatitis B, albeit further investigation is required. Novel therapeutic options targeting HDV life cycle are currently under clinical investigation. Baishideng Publishing Group Inc 2021-06-21 2021-06-21 /pmc/articles/PMC8218370/ /pubmed/34163109 http://dx.doi.org/10.3748/wjg.v27.i23.3249 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Almeida, Patricia Holanda Matielo, Celso E L Curvelo, Lilian A Rocco, Rodrigo A Felga, Guilherme Della Guardia, Bianca Boteon, Yuri L Update on the management and treatment of viral hepatitis |
title | Update on the management and treatment of viral hepatitis |
title_full | Update on the management and treatment of viral hepatitis |
title_fullStr | Update on the management and treatment of viral hepatitis |
title_full_unstemmed | Update on the management and treatment of viral hepatitis |
title_short | Update on the management and treatment of viral hepatitis |
title_sort | update on the management and treatment of viral hepatitis |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218370/ https://www.ncbi.nlm.nih.gov/pubmed/34163109 http://dx.doi.org/10.3748/wjg.v27.i23.3249 |
work_keys_str_mv | AT almeidapatriciaholanda updateonthemanagementandtreatmentofviralhepatitis AT matielocelsoel updateonthemanagementandtreatmentofviralhepatitis AT curveloliliana updateonthemanagementandtreatmentofviralhepatitis AT roccorodrigoa updateonthemanagementandtreatmentofviralhepatitis AT felgaguilherme updateonthemanagementandtreatmentofviralhepatitis AT dellaguardiabianca updateonthemanagementandtreatmentofviralhepatitis AT boteonyuril updateonthemanagementandtreatmentofviralhepatitis |